



SUPPLEMENTARY FIGURES



Supplementary Figure 1. Effects of omentin-1 on osteoblastic differentiation of HAVSMCs cultured with β -glycerophosphate (β -GP). (A) Effects of omentin-1 on the ALP activity in β -GP treated primary human arterial VSMCs (HAVSMCs). The cells were cultured with or without omentin-1 (100–400 ng/mL) for the indicated time points. ALP activity was measured by an ALP kit, normalized to the cellular protein contents. (B) Effects of omentin-1 on osteocalcin (OC) secretion in β -GP treated VSMCs. The cells were treated with or without omentin-1 (100–400 ng/mL) for 48 hours, and then OC secretion of the cells was determined by radioimmunoassay, normalized to the cellular protein contents. (C) Effect of omentin-1 on Runx2 expression in β -GP treated VSMCs. The cells were cultured for 48 hours with or without 100–400 ng/mL omentin-1. The data were presented as densitometric ratios of Runx2/ β -actin. (D) Effects of omentin-1 on calcium deposition. The cells were cultured for 21 days with β -GP or β -GP+omentin-1. Representative results were shown. (E) Alizarin Red S staining view of either β -GP or β -GP+omentin-1-treated VSMCs for 21 days. Representative microscopic pictures were shown. Results are represented by mean \pm SD with 3 replicates for each group. (* p < 0.05). One-way ANOVA with the Tukey’s HSD post hoc analysis was adopted.



Supplementary Figure 2. Expression of omentin-1 in omentin-1 deletion mice and in chronic kidney disease state of 5/6 NTP-induced mice. (A) Expression of omentin-1 in vesical adipose tissues of omentin-1 null mice. **(B)** Plasma mouse omentin-1 concentration in omentin-1^{-/-} mice and their littermates twelve weeks after sham operation or 5/6 nephrectomy (*p < 0.05 vs. sham control, n=6/per group, unpaired Student's t-test).